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Objectives
• Recognize im portance  of converting  IV to  PO 
m edications a t ISMC
• Discuss recen t rev isions to  th e  A utom atic 
Change of P aren tera l to  E nteral M edications in 
A dult P atien ts Policy and  P rocedure
• Locate p e rtin e n t inclusion and  exclusion crite ria  
in C erner
• Review facility p lan  for com pletion  of th e  IV to  
PO re p o rt
• Apply know ledge lea rn ed  by exam ple cases
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Advantages to Oral Administration:
• Oral fo rm ulations on the  m ark e t are  easie r to  
adm inister, safe, and  achieve desired  
th e rap eu tic  concen tra tions
• C om pared to  IV p rep ara tio n s, oral m edications
-  H ave d ecr e a se d  a sso c ia te d  r isk
-  A re b en efic ia l for p a tie n t an d  h o sp ita l
-  L ow er a sso c ia te d  co st
Journal o f  Pharm acology & Pharm acotherapeutics. 2014;5(2):83-87.
Kuper, KM. In trav en o u s to  Oral T h erapy  Conversion. Competence Assessm ent Tools fo r  Health System s Pharmacists. ASHP. 4 th  ed.; 2008:347-360. Available at: 
h ttp ://w w w .ash p .o rg /d o d ib ra ry /m em b ercen te r/d in ic a lsp ec ia lis tsan d sc ien tis ts /iv to p o .p d f._ A ccessed  N ovem ber 2, 2015. 3
Advantages to Oral Administration
D ecreased  Risk
• L ow er r isk  of 
se c o n d a ry  
in fec tion
• No in fu sion  
re la te d
a d v e rse  effects
• T re a tm e n t 
re s is ta n t  
o rg an ism s
P a tie n t F acto rs
• M ore 
co m fo rtab le
• Able to  
a m b u la te
• E arlie r 
d isch a rg e
E xpense
• G enerally  less  
expensive  
d o sag e  form
• D oesn 't 
re q u ire  IV sets , 
p u m p s, lab  
m o n ito r in g
• P re p a ra tio n  
tim e
BMC Health Services Research. 2005;5:48. 
Springerplus. 2014;3:717 4
Cost Comparison
Drug IV Cost ($) 
for Average LOS 
(6 days)
Cost ($)
IV X 2 days + 
PO X 4 days
Cost Savings ($) 
for 1 patient
Cost savings 





21 8 13 99,138




22 9 13 99,138
Ciprofloxacin 26 10 16 122,016 
400 mg IV q12h 
to 500 mg PO 
ql2h
Total Savings per year: $465, 186
M orris Dickson "5
Inclusion Criteria
• ALL req u irem en ts  m u st be m et
• Age > 18 years
• Overall im provem ent for reason  m edication  w as 
p resc rib ed
• H2 b lockers and  PPIs -> No GI bleeding, high 
gastric  residuals, o r NG o u tp u t




• ICU no longer excluded
• NPO sta tu s
• A ntibiotics for




• N eutropen ia
• Toxic Shock Syndrom e
Policy 0212
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Drugs Included in Policy
   Acetaminophen Folic acid
Azithromycin Levetiracetam
Ciprofloxacin Levofloxacin








• All doses and frequencies are the same for IV and PO except for 
the following:
IV PO
Acetaminophen 600-1000 mg 
Acetaminophen 325- 550 mg
Acetaminophen 650 mg 
Acetaminophen 325 mg
Ciprofloxacin 400 mg q8h 
Ciprofloxacin 400 mg 
Ciprofloxacin 200 mg
Ciprofloxacin 750 mg BID 
Ciprofloxacin 500 mg 
Ciprofloxacin 250 mg
Clindamycin 600 mg q6h or q8h 
Clindamycin 900 mg q8h
Clindamycin 300 mg q6h 
Clindamycin 450 mg q8h
Voriconazole 4 mg/kg Voriconazole
Patients < 40 kg: 100 mg q12h 




• Antibiotics in general
-  If an  in fec tio u s  d isea se s  p h y sic ian  is co n su lted  e n su re  
th e re  is no  specific  re a so n  for IV th e ra p y
-  Exam ple: C. difficile  in fec tion  re q u ir in g  o ra l vancom ycin  
an d  IV m e tro n id a z o le
• Fluoroquinolones
-  If rece iv in g  tu b e  feeding, c o n s id e r  w a itin g  on  
in te rc h a n g e  d u e  to  d ru g /fo o d  in te ra c tio n
• Vancomycin
-  N ot on th e  IV to  PO po licy
-  In d ica tio n s  fo r IV an d  PO a re  d iffe re n t an d  n o n ­
in te rc h a n g e a b le
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L ocating In form ation  in C erner
I. A ge





-  If PO E valu ate GI fu n c t io n :
1. M enu
2. R e su lts /F lo w sh e e ts
3. A ssessm en ts
4. G as tro in te s tin a l
-  IF NPO a n d  R ece iv in g  T u b e F eeds:
1. M enu
2. R e su lts /F lo w sh e e ts
3. A ssessm en ts
4. T ube  F eed ing  Info
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L ocating In form ation  in Cerner
I. V itals
1. M enu




2. R e su lts /F lo w sh e e ts
3. L ab o ra to ry  tab
III. C ultures
1. M enu
2. R e su lts /F lo w sh e e ts
3. M icrobiology
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P atien t Case # 1
AB is a 42 YOF ad m itted  to  ISMC for sh o rtn ess  of 
b rea th , fatigue, and  re sp ira to ry  d istress. She has 
a PMH significant for GERD and  HTN. An EGD 
w as done and  show ed  significant GI bleed. She 
has n o t had  any nausea, vom iting, o r d ia rrh ea  for 
the  last 24 hours. She is receiving a pan top razo le  
drip. Is she a cand idate  for an IV to PO 
in terchange for pan toprazo le?
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P atien t Case # 2
• ER is a 32 YOM b e in g  se e n  fo r a se v e re  
c a rb u n c le  in fec tio n  th a t  h a s  fa iled  I&D a n d  
p re v io u s  o ra l a n tib io tic  th e ra p ie s . T he  sk in  
c u ltu re s  cam e  b a c k  p o s itiv e  fo r MRSA a n d  
th e  p re s c r ib in g  d o c to r  w ish e s  to  c o n tin u e  
th e ra p y  w ith  L inezo lid  6 0 0 m g  IV q 1 2 h . 
W ould  h e  b e  a  c a n d id a te  fo r IV to  PO 
ch an g e?
14
Documentation Procedure
P harm acist should
• E n te r/m o d ify  o rd e r
• R oute— PO or Per Tube
• F requency should  stay  th e  sam e un less 
o therw ise  n o ted  in policy
• O rder com m ent: “IV to PO in terchange p e r  P&T 
protocol"
Physician o r designee m ay override  by rew ritin g  
o rd e r w ith  s ta tem en t “No PO" or “Do n o t change 
to  oral m edication"
Policy 0212
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C om pletion  o f IV to  PO R eport
• IV to  PO re p o rt has been  u p d a ted
-  A d d e d  n e w  m e d ic a t io n s
-  A d d e d  ICU f lo o rs
• A uto -p rin t tim e 0600 and  1730 daily
• Goals for com pletion
-  E v e n in g  s h if t  to  c o m p le te  o n  w e e k d a y s
-  D ay  s h if t  a n d  w e e k e n d  s ta f f  a s  t im e  a llo w s




• IV to  PO in terch a n g e  red u ces  IV re la ted  trea tm en t  
co m p lica tio n s, e n h a n c e s  p a tie n t co n v en ien ce , and  
m in im iz es  h o sp ita l and  h ea lth ca re  costs .
• M ed ica tion s a d d ed  to  th e  p o licy  in c lu d e  
a ce ta m in o p h en , c lin d am ycin , and  p a n to p ra zo le
• P a tien ts  in  th e  ICU are n o  lo n g er  ex c lu d ed  from  
th is  p o licy
• M any p a tien t factors can  b e  read ily  id en tified  in  
C erner
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